Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CTOR

Citius Oncology Inc

Feb 06 • 04:00PM ET

1.13

+0.02 1.80 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.34	Insider Own	81.22%	Shs Outstand	83.51M	Perf Week	6.60%
Market Cap	99.75M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.58M	Perf Month	-1.74%
Enterprise Value	99.63M	PEG	-	EPS next Q	-	Inst Own	9.97%	Short Float	7.25%	Perf Quarter	-26.62%
Income	-24.76M	P/S	-	EPS this Y	-	Inst Trans	0.56%	Short Ratio	2.62	Perf Half Y	-38.92%
Sales	0.00M	P/B	2.10	EPS next Y	-	ROA	-	Short Interest	1.20M	Perf YTD	13.00%
Book/sh	0.54	P/C	25.45	EPS next 5Y	-	ROE	-	52W High	6.19 -81.74%	Perf Year	-10.32%
Cash/sh	0.04	P/FCF	-	EPS past 3/5Y	- -309.67%	ROIC	-50.88%	52W Low	0.55 105.23%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.70% 7.81%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-77.52%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.11	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.08	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.56	EPS Q/Q	-	SMA20	2.91%	Beta	2.99	Target Price	6.00
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	-1.27%	Rel Volume	0.25	Prev Close	1.11
Employees	-	LT Debt/Eq	0.08	Earnings	Dec 23 AMC	SMA200	-29.42%	Avg Volume	458.73K	Price	1.13
IPO	Dec 08, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	113,236	Change	1.80%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-25	Upgrade	Maxim Group	Hold → Buy	$6
Nov-27-24	Initiated	Maxim Group	Buy	$3

Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
Dec-23-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire) -9.84%
Dec-10-25 04:30PM	Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Dec-09-25 08:30AM	Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) +6.42%
Dec-04-25 08:37AM	Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim (PR Newswire) -9.02%
12:00PM	Loading…
Dec-01-25 12:00PM	Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) (PR Newswire) +19.71%
Nov-25-25 08:00AM	Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting (PR Newswire) +8.04%
Nov-21-25 08:37AM	Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration (PR Newswire)
Oct-21-25 08:19AM	Citius Oncology finalises McKesson deal for Lymphir distribution (Pharmaceutical Business Review)
Oct-20-25 08:37AM	Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR Commercial Launch (PR Newswire) +5.29%
Oct-17-25 05:00PM	Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences (PR Newswire) -5.03%
Oct-16-25 08:47AM	Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR (PR Newswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-07-25 08:47AM	Citius Oncology Establishes International Access to LYMPHIR via Named Patient Programs in Southern Europe (PR Newswire)
Sep-10-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
08:30AM	Loading…
Sep-09-25 08:30AM	Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Aug-22-25 08:47AM	Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch (PR Newswire) +7.36%
Aug-12-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire) +5.92%
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire) +5.52%
Jul-17-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire)
Jul-16-25 09:15AM	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire)
Jul-15-25 08:32AM	Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora (PR Newswire) -20.62%
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire) +26.81%
Jun-17-25 08:08AM	Citius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 (PR Newswire)
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-09-25 08:37AM	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire) +17.13%
May-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Feb-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -5.60%
Feb-06-25 08:55AM	Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services (PR Newswire) -5.56%
08:08AM	Loading…
Jan-07-25 08:08AM	Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 (PR Newswire) -11.69%
07:57AM	Citius Oncology to explore strategic alternatives (TipRanks)
Jan-06-25 07:50AM	Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives (PR Newswire) +18.46%
Dec-31-24 07:10AM	Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital (TipRanks)
Dec-27-24 05:00PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire) +8.33% +7.69%
05:00PM	Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +6.30%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +8.38% -5.60%
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTOR

Citius Oncology Inc

Upgrade your FINVIZ experience